<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; CPIX</title>
	<atom:link href="http://www.stockbloghub.com/tag/cpix/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Tue, 22 May 2012 18:53:06 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(CAH) Cardinal Health and Cumberland Pharmaceuticals Sign Deal</title>
		<link>http://www.stockbloghub.com/2010/08/22/cah-cardinal-health-and-cumberland-pharmaceuticals-sign-deal-2/48444</link>
		<comments>http://www.stockbloghub.com/2010/08/22/cah-cardinal-health-and-cumberland-pharmaceuticals-sign-deal-2/48444#comments</comments>
		<pubDate>Sun, 22 Aug 2010 23:15:27 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[CPIX]]></category>
		<category><![CDATA[Cumberland Pharmaceuticals]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=48444</guid>
		<description><![CDATA[Cardinal Health (CAH), one of the largest distributors of pharmaceuticals and medical supplies, has reportedly inked a distribution agreement with Nashville, Tennessee-based Cumberland Pharmaceuticals (CPIX), a specialty pharmaceutical firm focused on the acute-care hospital and gastroenterology markets. Financial terms of the deal were not divulged by the companies. Under the three-year deal, Cardinal will exclusively distribute three of Cumberland’s drugs in the U.S, Puerto Rico and other specific countries. The drugs covered by the deal are Acetadote, Caldolor and Kristalose. Cumberland will be responsible for delivering these drugs to Cardinal’s distribution center in LaVergne, Tennessee. The deal represents another instance of the long-standing bond between the two companies. Cardinal teamed up with Cumberland in 2002 to market Kristalose (used to treat constipation and hepatic encephalopathy, a brain disorder) in the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/22/cah-cardinal-health-and-cumberland-pharmaceuticals-sign-deal-2/48444/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health and Cumberland Pharmaceuticals Sign Deal</title>
		<link>http://www.stockbloghub.com/2010/08/18/cah-cardinal-health-and-cumberland-pharmaceuticals-sign-deal/48250</link>
		<comments>http://www.stockbloghub.com/2010/08/18/cah-cardinal-health-and-cumberland-pharmaceuticals-sign-deal/48250#comments</comments>
		<pubDate>Wed, 18 Aug 2010 18:32:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[CPIX]]></category>
		<category><![CDATA[Cumberland Pharmaceuticals]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=48250</guid>
		<description><![CDATA[Cardinal Health (CAH), one of the largest distributors of pharmaceuticals and medical supplies, has reportedly inked a distribution agreement with Nashville, Tennessee-based Cumberland Pharmaceuticals (CPIX), a specialty pharmaceutical firm focused on the acute-care hospital and gastroenterology markets. Financial terms of the deal were not divulged by the companies. Under the three-year deal, Cardinal will exclusively distribute three of Cumberland’s drugs in the U.S, Puerto Rico and other specific countries. The drugs covered by the deal are Acetadote, Caldolor and Kristalose. Cumberland will be responsible for delivering these drugs to Cardinal’s distribution center in LaVergne, Tennessee. The deal represents another instance of the long-standing bond between the two companies. Cardinal teamed up with Cumberland in 2002 to market Kristalose (used to treat constipation and hepatic encephalopathy, a brain disorder) in the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/18/cah-cardinal-health-and-cumberland-pharmaceuticals-sign-deal/48250/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CPIX) Cumberland Pharmaceuticals&#8217; Ibuprofen Safety and Efficacy Beats Acetaminophen</title>
		<link>http://www.stockbloghub.com/2010/04/14/cpix-cumberland-pharmaceuticals-ibuprofen-safety-and-efficacy-beats-acetaminophen/33842</link>
		<comments>http://www.stockbloghub.com/2010/04/14/cpix-cumberland-pharmaceuticals-ibuprofen-safety-and-efficacy-beats-acetaminophen/33842#comments</comments>
		<pubDate>Wed, 14 Apr 2010 22:37:01 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CPIX]]></category>
		<category><![CDATA[Cumberland Pharmaceuticals]]></category>
		<category><![CDATA[Hospira Inc.]]></category>
		<category><![CDATA[HSP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=33842</guid>
		<description><![CDATA[Recently, Cumberland Pharmaceuticals Inc. (CPIX) announced results from a meta-analysis comparing the safety and efficacy of Caldolor (ibuprofen) and acetaminophen. The data, which was published in the March edition of The Annals of Pharmacotherapy, revealed that ibuprofen was more effective than acetaminophen for the treatment of pain and fever. The newly published meta-analysis was based on 85 published studies that compared oral ibuprofen with oral acetaminophen for analgesic efficacy, antipyretic efficacy and safety in adult as well as pediatric populations. Cumberland stated that the data reinforced the findings from previously published studies on the efficacy of Caldolor injection for the treating pain and fever. As a reminder, the US Food and Drug Administration (FDA) had approved Caldolor, the intravenous formulation of ibuprofen, in June 2009. The product, launched in September ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/14/cpix-cumberland-pharmaceuticals-ibuprofen-safety-and-efficacy-beats-acetaminophen/33842/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CPIX) Cumberland Pharmaceuticals Beats Consensus Estimate</title>
		<link>http://www.stockbloghub.com/2009/11/30/cpix-cumberland-pharmaceuticals-beats-consensus-estimate/21523</link>
		<comments>http://www.stockbloghub.com/2009/11/30/cpix-cumberland-pharmaceuticals-beats-consensus-estimate/21523#comments</comments>
		<pubDate>Mon, 30 Nov 2009 16:22:10 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CPIX]]></category>
		<category><![CDATA[Cumberland Pharmaceuticals]]></category>
		<category><![CDATA[Hospira Inc.]]></category>
		<category><![CDATA[HSP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=21523</guid>
		<description><![CDATA[Cumberland Pharmaceuticals Inc. (CPIX) reported third quarter earnings of 10 cents per share, well above the Zacks Consensus Estimate of 1 cent. Revenues for the quarter came in at $13.6 million as against $8.6 million in the comparable quarter of 2008, up 58%. The increase in revenues for the quarter was attributable to the initial sales from Caldolor injection, the intravenous formulation of ibuprofen, coupled with the increased usage of Acetadote, an injectable drug intended to counter the overdoses of acetaminophen. The U.S. Food and Drug Administration (FDA) approved Caldolor in Jun 2009. The product, launched in Sep, is the first injectable product available in the U.S. for treating pain and fever. The injection is used primarily for treating hospitalized patients who cannot receive oral drugs for reducing pain and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/30/cpix-cumberland-pharmaceuticals-beats-consensus-estimate/21523/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CPIX) Encouraging Results for Cumberland Pharmaceuticals</title>
		<link>http://www.stockbloghub.com/2009/11/29/encouraging-results-for-cumberland-pharmaceuticals/21431</link>
		<comments>http://www.stockbloghub.com/2009/11/29/encouraging-results-for-cumberland-pharmaceuticals/21431#comments</comments>
		<pubDate>Mon, 30 Nov 2009 04:34:29 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CPIX]]></category>
		<category><![CDATA[Cumberland Pharmaceuticals]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=21431</guid>
		<description><![CDATA[Recently, Cumberland Pharmaceuticals Inc (CPIX) announced that Caldolor (Ibuprofen), its candidate for treating pain and fever, reduced fever in burn patients over the first 24 hours of treatment in a multi-center, randomized, double-blind study. The drug, an intravenous therapy, was well tolerated and is fit enough to be administered to hospitalized burn patients for five consecutive days without any safety concerns. The 61 adult burn patients evaluated in the study suffered from second or third degree burns covering more than 10% of the body surface area. The study also comprised of a few subjects who anticipated a hospital stay in excess of 3 days and temperatures greater than or equal to 100.40 F. The patients were administered with 800 milligrams of Caldolor injection every six hours for five consecutive days. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/29/encouraging-results-for-cumberland-pharmaceuticals/21431/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

